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Purpose: We demonstrate a new approach for assessing and visualizing visual field
(VF) progression in clinics.
Methods: Two summary measures for VF progression, Rate of Progression (RP) and
Loss of Sight Years (LSY), are combined with a novel visualization (Hedgehog Plots).
RP is calculated per eye using linear regression of mean deviation (MD) against time of
follow-up. LSY is a novel parameter, linked to actuarial data, which estimates the
number of years that a patient will have advanced bilateral VF loss in their predicted
remaining lifetime. Every eye is given a rank within the sample based on RP and LSY
allowing for ‘‘priority’’ patients to be identified. We illustrate differences between the
parameters with an experiment comparing the cases flagged as ‘‘priority’’ by each
method using data from 1263 VF records.
Results: RP for every eye in a ‘‘clinic’’ can be visualized and assessed using a
Hedgehog Plot. Eyes are ranked against all other eyes by RP and LSY; these
parameters provide different and complementary information on a patient’s VF
progression status. A purpose written interactive application demonstrating the
techniques is available in the public domain at https://crabblab.shinyapps.io/
hedgehog.
Conclusion: Hedgehog Plots provide a tool for visualizing VF progression in groups of
patients and can be used potentially to prioritize monitoring resources.
Translational Relevance: This study illustrates a novel visualization technique and an
interactive application that can be used to help determine VF progression in large
groups of patients.
Introduction
The primary method for determining functional
deterioration in glaucoma is evaluation of series of
visual fields (VF) as measured by standard automated
perimetry. Treatment for disease progression in
glaucoma involves attempting to reduce the only
modifiable risk factor, intraocular pressure (IOP).1,2
Regular monitoring usually is required throughout
the course of the disease prompting adjustment of
treatment in line with the detection of any worsening
in the patient’s VF. However, regular VF monitoring
of all glaucoma patients results in a huge patient
management workload.3 Hence, a tool for optimizing
the use of resources would be beneficial within clinics.
A commonly used summary measure for assessing
the severity of VF loss is the mean deviation (MD);
this is a measure of the overall VF loss, relative to
healthy age-matched observers, with more negative
values indicating greater VF loss. Clinicians and
researchers in glaucoma are universally familiar with
the MD, and its strengths and limitations are well
understood.4 By plotting MD acquired at different
examinations over time, it is possible to determine a
speed or rate of VF loss per eye. This is not a new
idea.5,6 Ways of doing this in individual eyes exist in
some perimetry software.7 Yet a tool for comparing
rate of VF loss of all eyes in a clinic would be useful
for prioritizing follow-up resources. Such a tool does
not exist. Furthermore, it is important to consider the
VF loss in both eyes when evaluating progression. A
person’s visual function may only become compro-
mised as VFs in both eyes deteriorate.8 VF progres-
sion software has failed to consider this in the past.
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We demonstrate a new approach for assessing VF
progression in clinics using two parameters designed
to be easily understood: Rate of Progression (RP:
MD loss [B] per year) and Loss of Sight Years (LSY).
These parameters are presented in a novel visualiza-
tion (Hedgehog Plot) and we illustrated how they
might be used to help determine patients requiring
more or less monitoring. In this study, we also
demonstrated how RP and LSY offer complementary
but different information on the patient’s VF
progression status. Furthermore, we presented a free
web-based software application that can demonstrate
and implement these techniques.
Materials and Methods
To illustrate our methods we used a sample of data
from a population of 88,954 patients extracted from
Medisoft VF databases (Medisoft Ltd., Leeds, UK)
from four regionally different clinics in England.
These data have been described in detail previously9,10
and were recorded during a period of approximately
12 years before the extraction date in 2012. Data
access was granted by the Caldicott Guardians at
each center. All patient data were anonymized and
transferred to a single secure database. The research
procedures followed the tenets set forth in the
Declaration of Helsinki and was approved by a
research governance committee of City, University of
London. For the purpose of this study, only VFs
tested by using the Humphrey Field Analyzer (Carl
Zeiss Meditec, Dublin, CA) with the 24-2, white-on-
white test strategy acquired with the Swedish Inter-
active Testing Algorithm (SITA Standard or SITA
Fast) were included in the analysis. Patients were
required to be between the ages of 45 and 90 years and
have a follow-up of at least 2 years for inclusion into
the present study. Furthermore, each VF series was
required to have at least three examinations (visits)
after the first was discarded to reduce perimetric
learning effects.11,12 From the eligible data, 200 eyes
from 100 individuals (1263 VFs) were selected
randomly for our illustrative analyses. Note that all
data were anonymized and examination dates were
perturbed to ensure anonymity.
Rates of MD loss were calculated per eye in
decibels per year (dB/y) using ordinary least squares
regression. The regression lines were plotted using a
novel data visualization tool, the Hedgehog Plot.
Each line in this plot represents an eye, with the length
of the line indicating the length of follow-up in years.
The location of the line is aligned to the patient’s age
(horizontal axis) and severity of initial VF loss
(vertical axis). The slope of the line indicates the rate
of progression with, for example, steeply declining
lines indicating rapidly changing eyes. This tool
allowed us to visualize the progression rates for all
eyes simultaneously. An illustration of this is shown
in Figure 1.
Loss of Sight Years (LSY) is a novel parameter,
linked to residual life expectancy data. LSY estimates
the number of years that a patient will have bilateral
VF loss worse than MD of 22 dB (binocular VF
impairment) in their predicted remaining lifetime.13
Both eyes reaching this threshold is considered to be
the benchmark for ‘‘statutory blindness’’ by the
United States Social Security Administration (US
SSA).14 Assuming the RP remains constant, we
Figure 1. A schematic illustrating how the Hedgehog Plots are
created. (A) A real example from the clinic showing the
progression rate estimated for one eye. The first and last VFs for
this patient were taken at the ages of 50 and 55 years, respectively.
(B) Each line represents one of the 100 eyes within the clinic.
2 TVST j 2018 j Vol. 7 j No. 1 j Article 22
Bryan and Crabb
Downloaded From: http://tvst.arvojournals.org/pdfaccess.ashx?url=/data/journals/tvst/936672/ on 03/01/2018
predicted the age at which each patient will reach an
MD of22 dB in their better eye. We then estimated
each patient’s residual life expectancy, which was
expected to differ depending on the current age of the
person. For example, a 45-year-old female is expected
to live to 84 while a 90-year-old female is expected to
live to 94. For the purposes of this work median
residual life expectancies, based on age and sex, were
collected from the UK Office of National Statistics.15
These were derived using the latest available English
census data. LSY is then calculated as the number of
years between the predicted age at which the patient
will reach binocular VF impairment and the patient’s
expected age of death (see Fig. 2).
Using the Hedgehog Plot, we can instantaneously
flag the most rapid progressors within the clinic
allowing for ‘‘at risk’’ patients to be identified easily.
This is based on the progression rate estimated for
each eye. However, looking at the progression rates
alone does not take into account the disease severity
at baseline. LSY considers the patient’s age and the
patient’s baseline measurements. Hence, we also can
flag individuals who have a LSY . 0; that is
individuals predicted to have binocular VF impair-
ment within their residual expected lifetime.
LSY likely offers different information to RP. For
example, an older patient may be flagged as having
rapid progression but may never reach predicted
binocular VF impairment within their residual
expected lifetime. Conversely a younger patient with
a moderate progression rate may suffer from signif-
icant visual impairment for a prolonged period of
time. To test for differences in the information given
by RP and LSY we calculated the concordance
between the two measures in flagging patients as
what we define ‘‘priority cases.’’ Individuals are first
flagged as a ‘‘priority case’’ based on the RP in their
eye with the least VF damage (the least affected eye
with the better MD at the last VF examination16)
progressing faster than a threshold of1 dB per year.
We then calculated the percentage of these patients
who are defined as a ‘‘priority case’’ on LSY, that is
they have a LSY . 0. We repeated this for a different
threshold, namely when RP is worse than0.5 dB/y.
We also compared the baseline ages and MD at
presentation of the individuals flagged as a ‘‘priority
case’’ by each method.
Results
RP for every eye in a ‘‘clinic’’ is shown in a
Hedgehog Plot (Fig. 3A). Here, we demonstrated how
the Hedgehog Plot can be used to visualize data and
indicate patients with progression at different rates.
Eyes are colored depending on the rate of progression
(Fig. 3B–F). Green indicated eyes that are stable/
learning (slope . 0 dB/y); gray indicated eyes that
with slow progression (0.5, slope, 0 dB/y); yellow
indicated eyes with moderate progression (1 , slope
, 0.5 dB/y), and red indicated eyes with fast
progression (1 . slope). (An increasing RP [green]
is likely due to variability or a learning effect rather
than an improvement in MD.) It is interesting to note
in our data 39% of eyes have a VF series that is green.
These patients are likely stable and may not require
increased monitoring, for example.
The application also allows the user to select and
highlight individual eyes/patients and compare their
progression to data from the entire clinic. Eyes are
ranked against all other eyes by RP and LSY. The
application can automatically highlight the two lines
belonging to an individual patient. Figure 4 shows a
patient who has rapid visual progression in one eye
(ranked the 10th fastest progressing eye within this
clinic). However, since they have slow progression in
the second eye (ranked 54th within this clinic), they
are not predicted to reach binocular VF impairment
within their expected lifetime (LSY of 0 years). In
Figure 5, the patient has rapid visual progression in
both eyes (ranked the seventh and eighth fastest
progressing eyes within this clinic). Due to the age of
the patient they are not likely to reach binocular VF
impairment within their expected lifetime (LSY of 0
Figure 2. A schematic illustrating the calculation of LSY using a
real patient from the clinic. In this example, the right eye was
anticipated to have progression to the binocular VF impairment
stage by the end of the patient’s life. However, given that the VF of
the left eye is stable and has less VF damage at diagnosis, this
patient would be unlikely to experience visual impairment during
their lifetime.
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Figure 3. (A) Hedgehog Plot showing rate of VF progression status in a sample of 200 eyes from 100 patients. (B) All eyes are colored
depending on the rate of progression. This can be divided into (C) eyes that are stable/improving (slope . 0 dB/y), (D) eyes with slow
progression (0.5 , slope , 0 dB/y), (E) eyes with moderate progressoion (1 , slope ,0.5 dB/y), and (F) eyes with fast progression
(1 , slope).
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years). In Figure 6, a younger patient is shown, aged
55 years at the most recent VF examination. This
patient has relatively slowly progressing eyes (ranked
23rd and 46th, respectively) but considerable VF
damage at diagnosis (worse that12 dB). This patient
is predicted to suffer from binocular VF impairment
for 10 years within their expected lifetime. So, this
patient might be highlighted to warrant more careful
monitoring (more frequent VFs), or intensified
treatment.
To compare RP and LSY, we flagged patients as
‘‘priority cases’’ if RP in their better eye was worse
than a certain threshold or they were predicted to
have LSY . 0. In Figure 7, the individuals flagged
according to RP in their best eye are shown in purple.
Figures 7A and 7B highlight individuals flagged based
on varying thresholds for the RP (A, ,1 dB/y; B, ,
0.5 dB/y). Individuals with a LSY . 0 are shown in
cyan. The patients flagged by both parameters are
shown in black. (Note, for clarity only the ‘‘best eye’’
per patient is shown as if this eye falls below22 dB
the patient would be considered to have binocular VF
impairment.)
To summarize the results from Figure 7, four
patients (4%) were identified as being ‘‘priority’’ when
a threshold of worse than 1 dB/y was set for the
better eye but only two of these (50%) had a LSY. 0.
Fourteen (14%) patients were identified as being
‘‘priority’’ when a threshold of worse than0.5 dB/y
was set for the better eye, but only four of these (29%)
had a LSY . 0. This showed that the two parameters
give different information.
There were differences in the baseline ages and
MD at presentation in patients flagged by RP using a
threshold of ,1 dB/y and LSY. Mean (SD) age for
the individuals flagged as a ‘‘priority case’’ based on
RP and on LSY was 76 (7) and 64 (14) years,
respectively. Mean baseline MDs were 4.0 dB (3.1
dB) and 10.4 dB (8.9 dB) for individuals flagged
based on the RP and LSY, respectively. LSY,
therefore, highlights younger patients or patients with
more severe damage at presentation.
A purpose written interactive application demon-
strating the techniques is available in the public
Figure 4. Patient 38 has rapid visual progression in one eye
shown in red (ranked 10th within this clinic). However, the second
eye, shown in gray, is progressing slowly (ranked 54th within this
clinic), so this patient has a LSY of 0 years.
Figure 5. Patient 84 has rapid visual progression in both eyes
(ranked seventh and eighth worst eyes within this clinic). However,
this patient has a LSY of 0 years.
Figure 6. Patient 54 has relatively slowly/moderately progressing
eyes (ranked 23rd and 46th, respectively), but considerable visual
field damage at diagnosis (worse than 12 dB); the patient is
relatively young. This patient is predicted to have bilateral
blindness for 10 years within their expected lifetime. So, this
patient might be highlighted to warrant more careful monitoring
(more frequent VFs), or intensified treatment, to prevent loss of
sight.
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domain at https://crabblab.shinyapps.io/hedgehog.
This application contains the demonstration dataset
used in this report. However, the application has been
written to allow a user to import and analyze their
own dataset using the application. A video (available
in the public domain at https://youtu.be/zgzEOh
fYf4w) as well as a document (available in the public
domain at https://crabblab.shinyapps.io/hedgehog
README) explaining the results and how to import
the data also is provided. In this instance we have not
recommended inclusion and exclusion criteria for VFs
but prudent use would consider VF reliability indices,
for example. This application is intended for infor-
mational, educational, and research purposes only. It
is not, and is not intended, for use in the diagnosis of
disease or other conditions. Health care providers
should exercise their own independent clinical judg-
ment when using the application in conjunction with
patient care.
Discussion
Previous research from glaucoma clinics in Eng-
land has suggested most patients get a similar ‘‘diet’’
of VF testing over time.17 For example, average
number of VF examinations over time has been
similar for all patients, irrespective of age, severity of
VF loss, and rate of MD loss.17 This ‘‘one size fits all’’
approach to glaucoma follow-up for VF testing is
likely suboptimal from a clinical18 and health
economic19 perspective. Hedgehog Plots provide a
potential novel tool for clinicians to visualize all their
glaucoma patients simultaneously. Hedgehog Plots
could be helpful in selecting patients who should be
seen more or less frequently in follow-up, allowing for
the prioritization of monitoring resources. In this
study, we also present two parameters, RP and LSY.
The former is not novel,5,6 but it is an important
concept for clinicians to incorporate into glaucoma
management decisions. LSY is novel and we have
shown that it offers complementary but different
information to RP.
Key to this work and additional to this report is
provision of a purpose written interactive application
demonstrating the techniques. We hope this applica-
tion stimulates design of similar software that could
be used in clinics. After all, we know software helps
provide a way to standardize clinical assessment and
has been proven to improve the agreement between
clinicians when making decisions about VF progres-
sion occurring.20 Our application is also designed to
allow clinicians to analyze data within their own
clinics if MD data entry can be completed. Realisti-
cally our tool will only be widely adopted if a version
is incorporated into clinically used software, like an
electronic medical record (EMR) or in ophthalmic
data management systems linked to perimeters. At
that stage other design features, such as resetting the
baseline of a VF series to times of significant changes
in therapy in long-term follow-up, could be consid-
ered. Moreover, the software ought to be designed
such that a clinician can easily exclude unreliable VF
examinations or, for example, use published tech-
niques for minimizing the effects of outlier observa-
tions.21
RP can be ranked for all patients in a clinic to help
identify worse cases of VF progression without using
inferential statistics. This allows for a comparison
between individuals and the general clinical popula-
tion rather than imposing an arbitrary cutoff based
on a P value. Such ranking could be useful in
Figure 7. Regression lines with age on the x-axis with patients
with LSY . 0 highlighted in cyan, progressors highlighted in
purple, and the overlap between the two parameters in black.
Varying limits for the RP are used: (A) ,1 dB/y, (B) ,0.5 dB/y.
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situations where decisions must be made about
allocation of VF monitoring resources. For example,
more frequent examinations may be allocated to
someone with an observed fast rate of progression or
a ‘‘priority case.’’ Furthermore, a patient who seems
to have rapid progression in their better eye would
need more monitoring than a person who shows no
progression in either eye. Further refinement can be
achieved by using LSY. A specific example of this is
given in Figure 4, where Patient 84 has rapid visual
progression in both eyes (ranked the seventh and
eighth worst eyes within this clinic). However, this
patient was predicted to have a LSY of 0 years.
Patient 54 had relatively slowly progressing eyes
(ranked 23rd and 46th, respectively) but considerable
VF damage at diagnosis (worse that 12 dB); the
patient is relatively young. This patient is predicted to
have bilateral blindness for 10 years within their
expected lifetime. So, this patient might warrant more
careful monitoring (more frequent VFs) or intensified
treatment. In addition to the applications we have
shown here, the Hedgehog Plot could be used as a
tool to compare different clinics by using a large data
set as a reference clinic.10 This would allow clinicians
to compare results of their own patients directly to
those of others, or could be used for auditing
purposes. Hedgehog Plots also might be useful for
comparing the entire distribution of VF progression
in different arms of a clinical trial.
We used an MD worse than22 dB as a potential
definition of visual impairment, but different cutoff
values could be used. This threshold was based on the
US SSA benchmark, which defines ‘‘statutory blind-
ness’’ as both eyes reaching this cutoff value.14 Other
criteria, linked to ability to perform functional tasks
could be used.22–25 For example, individuals who
reach a MD threshold of worse than14 dB in both
eyes are unlikely to satisfy the VF component for
adequate vision to be legally fit to drive in the United
Kingdom.26 Of course this limit will vary by country
depending on regulations. Further research in this
area would be of interest.
In this study, we used MD measurements, which
are well known and well understood by clinicians. The
MD is only a summary measure of the VF and is a
weighted average across the VF, relative to a group of
healthy age-matched individuals. However, the indi-
vidual VF points may be of greater interest, because
of the additional information they provide, such as
the spatial nature of VF loss. This information is
otherwise lost in global parameters. Although we
assume binocular VF impairment at 22 dB, the
patient still may have some preserved visual function
at this threshold. The remaining visual function may
be significantly affected by the location of the VF
damage.27–29 For example, more centrally located
progression would arguably affect the patient’s
quality of life more significantly than peripherally
located progression. Additionally, if progression took
place in matching locations in each eye, this local
progression would likely affect the patient’s visual
function more significantly than where no such
binocular defects existed.8,30
The assumption of a linear rate of progression in
predicting VF loss is another limitation of this study.
While this may not be representative of true
glaucomatous VF deterioration, it is used commonly
in clinical practice and has been shown to provide
more robust estimates of future measurements than
more complex models.31,32 Furthermore, we assumed
that the RP is constant throughout the patient’s
predicted remaining lifetime. This may underestimate
true deterioration. It also does not take into account
future amelioration of progression by intensified
treatment. For example, a glaucoma patient, possibly
nonadherent or nonresponsive to treatment, may
have a significant reduction in RP after intensified
treatment.33 In turn, this could affect their course to
predicted significant LSY because RP and LSY are
inherently linked. In this situation it might be prudent
to consider a new baseline VF assessment. Conversely
an eye that, for example, suffers ocular comorbidity
or rapid vision loss due to cataract, even late in life,
may result in a rapidly changing RP and unexpected
LSY. Our tool, therefore, is limited because it does
not solve these unchanging dilemmas of managing
glaucoma. Yet, as a visualization tool, used in
conjunction with other patient data, it still may offer
the managing clinician useful information that may
have remained unseen in a series of VF charts.
It also is important to note that our life expectancy
data were determined using UK census data and will
not be representative of populations in other coun-
tries. Furthermore, the clinic data we use were
extracted from clinics across England. These may
not be representative of different demographics and
different health care systems. This should be taken
into account particularly for interclinic comparisons.
Conclusions
In conclusion, this study demonstrated a new
approach for assessing VF progression in clinics.
Differences between selecting patients as ‘‘priority’’
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cases using RP and LSY emphasize the importance of
choosing the appropriate criteria for summarizing
progression. We illustrated these techniques with a
novel visualization tool and provide an interactive
application that can be used in clinical practice.
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